메뉴 건너뛰기




Volumn 46, Issue 7, 2007, Pages 951-960

Treatment schedule is of importance when gefitinib is combined with irradiation of glioma and endothelial cells in vitro

Author keywords

[No Author keywords available]

Indexed keywords

CELL NUCLEUS DNA; DNA FRAGMENT; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEFITINIB;

EID: 35148830050     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.1080/02841860701253045     Document Type: Article
Times cited : (14)

References (25)
  • 1
    • 0035153624 scopus 로고    scopus 로고
    • Assessment of alterations in gene expression in recurrent malignant glioma after radiotherapy using complementary deoxyribonucleic acid microarrays
    • Discussion 201-2
    • Joki T, Carroll RS, Dunn IF, Zhang J, Abe T, Black PM. Assessment of alterations in gene expression in recurrent malignant glioma after radiotherapy using complementary deoxyribonucleic acid microarrays. Neurosurgery 2001;48:195-201; Discussion 201-2.
    • (2001) Neurosurgery , vol.48 , pp. 195-201
    • Joki, T.1    Carroll, R.S.2    Dunn, I.F.3    Zhang, J.4    Abe, T.5    Black, P.M.6
  • 3
    • 0025686126 scopus 로고
    • Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts
    • Bigner SH, Humphrey PA, Wong AJ, Vogelstein B, Mark J, Friedman HS, et al. Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts. Cancer Res 1990;50:8017-22.
    • (1990) Cancer Res , vol.50 , pp. 8017-8022
    • Bigner, S.H.1    Humphrey, P.A.2    Wong, A.J.3    Vogelstein, B.4    Mark, J.5    Friedman, H.S.6
  • 5
    • 0034068319 scopus 로고    scopus 로고
    • Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor
    • Ciardiello F, Caputo R, Bianco R, Damiano V, Pomatico G, De Placido S, et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 2000;6:2053-63.
    • (2000) Clin Cancer Res , vol.6 , pp. 2053-2063
    • Ciardiello, F.1    Caputo, R.2    Bianco, R.3    Damiano, V.4    Pomatico, G.5    De Placido, S.6
  • 6
    • 8644234228 scopus 로고    scopus 로고
    • Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for Gefitinib (Iressa®, ZD1839) in chemotherapy-resistant non-small cell lung cancer
    • Han SW, Hwang PG, Chung DH, Kim DW, Im SA, Kim YT, et al. Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for Gefitinib (Iressa®, ZD1839) in chemotherapy-resistant non-small cell lung cancer. Int J Cancer 2005;113:109-15.
    • (2005) Int J Cancer , vol.113 , pp. 109-115
    • Han, S.W.1    Hwang, P.G.2    Chung, D.H.3    Kim, D.W.4    Im, S.A.5    Kim, Y.T.6
  • 7
    • 0035476803 scopus 로고    scopus 로고
    • The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signalling and suppresses the growth of HER2-overexpressing tumor cells
    • Moasser MM, Basso A, Averbuch SD, Rosen N. The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signalling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res 2001;61:7184-8.
    • (2001) Cancer Res , vol.61 , pp. 7184-7188
    • Moasser, M.M.1    Basso, A.2    Averbuch, S.D.3    Rosen, N.4
  • 8
    • 0242442483 scopus 로고    scopus 로고
    • Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant glioma
    • Li B, Chang CM, Yuan M, McKenna WG, Shu HK. Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant glioma. Cancer Res 2003;63:7443-50.
    • (2003) Cancer Res , vol.63 , pp. 7443-7450
    • Li, B.1    Chang, C.M.2    Yuan, M.3    McKenna, W.G.4    Shu, H.K.5
  • 10
    • 2442482627 scopus 로고    scopus 로고
    • Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme
    • Learn CA, Hartzell TL, Wikstrand CJ, Archer GE, Rich JN, Friedman AH, et al. Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme. Clin Cancer Res 2004;10:3216-24.
    • (2004) Clin Cancer Res , vol.10 , pp. 3216-3224
    • Learn, C.A.1    Hartzell, T.L.2    Wikstrand, C.J.3    Archer, G.E.4    Rich, J.N.5    Friedman, A.H.6
  • 12
    • 0344430039 scopus 로고    scopus 로고
    • Time and dose-dependent radiosensitization of the glioblastoma multiforme U251 cells by the EGF receptor tyrosine kinase inhibitor ZD1839 ('Iressa')
    • Stea B, Falsey R, Kislin K, Patel J, Glanzberg H, Carey S, et al. Time and dose-dependent radiosensitization of the glioblastoma multiforme U251 cells by the EGF receptor tyrosine kinase inhibitor ZD1839 ('Iressa'). Cancer Lett 2003;202:43-51.
    • (2003) Cancer Lett , vol.202 , pp. 43-51
    • Stea, B.1    Falsey, R.2    Kislin, K.3    Patel, J.4    Glanzberg, H.5    Carey, S.6
  • 13
    • 0027428571 scopus 로고
    • Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts
    • Fan Z, Baselgam J, Masui H, Mendelsohn J. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res 1993;53:4637-42.
    • (1993) Cancer Res , vol.53 , pp. 4637-4642
    • Fan, Z.1    Baselgam, J.2    Masui, H.3    Mendelsohn, J.4
  • 14
    • 0002636457 scopus 로고    scopus 로고
    • Radio-sensitivity and cell age in the mitotic cycle
    • 5th ed. Philadelphia: Lippincott Williams & Wilkins;
    • Hall EJ. Radio-sensitivity and cell age in the mitotic cycle. Radiobiology for the Radiobiologist. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2000. p. 51-66.
    • (2000) Radiobiology for the Radiobiologist , pp. 51-66
    • Hall, E.J.1
  • 15
    • 0037499945 scopus 로고    scopus 로고
    • Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: Limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways
    • Janmaat ML, Kruyt FA, Rodriguez JA, Giaccone G. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: Limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways. Clin Cancer Res 2003;9:2316-26.
    • (2003) Clin Cancer Res , vol.9 , pp. 2316-2326
    • Janmaat, M.L.1    Kruyt, F.A.2    Rodriguez, J.A.3    Giaccone, G.4
  • 16
    • 0037029703 scopus 로고    scopus 로고
    • Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839 ("Iressa")
    • Magne N, Fischel JL, Dubreuil A, Formento P, Poupon MF, Laurent-Puig P, et al. Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839 ("Iressa"). Br J Cancer 2002;86:1518-23.
    • (2002) Br J Cancer , vol.86 , pp. 1518-1523
    • Magne, N.1    Fischel, J.L.2    Dubreuil, A.3    Formento, P.4    Poupon, M.F.5    Laurent-Puig, P.6
  • 17
    • 0036681993 scopus 로고    scopus 로고
    • The epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a RAS-dependent manner
    • Chakravarti A, Chakladar A, Delaney MA, Latham DE, Loeffler JS. The epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a RAS-dependent manner. Cancer Res 2002;62:4307-15.
    • (2002) Cancer Res , vol.62 , pp. 4307-4315
    • Chakravarti, A.1    Chakladar, A.2    Delaney, M.A.3    Latham, D.E.4    Loeffler, J.S.5
  • 19
    • 0027412319 scopus 로고
    • Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: A model of glioblastoma multiforme pathophysiology
    • Goldman CK, Kim J, Wong WL, King V, Brock T, Gillespie GY. Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: A model of glioblastoma multiforme pathophysiology. Mol Biol Cell 1993;4:121-33.
    • (1993) Mol Biol Cell , vol.4 , pp. 121-133
    • Goldman, C.K.1    Kim, J.2    Wong, W.L.3    King, V.4    Brock, T.5    Gillespie, G.Y.6
  • 20
    • 0034212763 scopus 로고    scopus 로고
    • Blockade of the epidermal growth factor receptor signalling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma
    • Bruns CJ, Solorzano CC, Harbison MT, Ozawa S, Tsan R, Fan D, et al. Blockade of the epidermal growth factor receptor signalling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res 2000;60:2926-35.
    • (2000) Cancer Res , vol.60 , pp. 2926-2935
    • Bruns, C.J.1    Solorzano, C.C.2    Harbison, M.T.3    Ozawa, S.4    Tsan, R.5    Fan, D.6
  • 21
    • 0020081554 scopus 로고
    • Endothelial cell proliferation as a novel approach to targeting tumour therapy
    • Denekamp J. Endothelial cell proliferation as a novel approach to targeting tumour therapy. Br J Cancer 1982;45:136-9.
    • (1982) Br J Cancer , vol.45 , pp. 136-139
    • Denekamp, J.1
  • 22
    • 0020449692 scopus 로고
    • Endothelial cell proliferation in experimental tumours
    • Denekamp J, Hobson B. Endothelial cell proliferation in experimental tumours. Br J Cancer 1982;46:711-20.
    • (1982) Br J Cancer , vol.46 , pp. 711-720
    • Denekamp, J.1    Hobson, B.2
  • 23
    • 0036842170 scopus 로고    scopus 로고
    • Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types
    • Baselga J, Rischin D, Ranson M, Calvert H, Raymond E, Kieback DG, et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 2002;20:4292-302.
    • (2002) J Clin Oncol , vol.20 , pp. 4292-4302
    • Baselga, J.1    Rischin, D.2    Ranson, M.3    Calvert, H.4    Raymond, E.5    Kieback, D.G.6
  • 24
    • 1542503746 scopus 로고    scopus 로고
    • Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT 1
    • Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT 1. J Clin Oncol 2004;22:777-84.
    • (2004) J Clin Oncol , vol.22 , pp. 777-784
    • Giaccone, G.1    Herbst, R.S.2    Manegold, C.3    Scagliotti, G.4    Rosell, R.5    Miller, V.6
  • 25
    • 2342471392 scopus 로고    scopus 로고
    • Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
    • Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
    • (2004) N Engl J Med , vol.350 , pp. 2129-2139
    • Lynch, T.J.1    Bell, D.W.2    Sordella, R.3    Gurubhagavatula, S.4    Okimoto, R.A.5    Brannigan, B.W.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.